Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation

Mark Jesus M Magbanua, Ritu Roy, Eduardo V Sosa, Vivian Weinberg, Scott Federman, Michael D Mattie, Millie Hughes-Fulford, Jeff Simko, Katsuto Shinohara, Christopher M Haqq, Peter R Carroll, June M Chan, Mark Jesus M Magbanua, Ritu Roy, Eduardo V Sosa, Vivian Weinberg, Scott Federman, Michael D Mattie, Millie Hughes-Fulford, Jeff Simko, Katsuto Shinohara, Christopher M Haqq, Peter R Carroll, June M Chan

Abstract

Background: Studies suggest that micronutrients may modify the risk or delay progression of prostate cancer; however, the molecular mechanisms involved are poorly understood. We examined the effects of lycopene and fish oil on prostate gene expression in a double-blind placebo-controlled randomized clinical trial.

Methods: Eighty-four men with low risk prostate cancer were stratified based on self-reported dietary consumption of fish and tomatoes and then randomly assigned to a 3-month intervention of lycopene (n = 29) or fish oil (n = 27) supplementation or placebo (n = 28). Gene expression in morphologically normal prostate tissue was studied at baseline and at 3 months via cDNA microarray analysis. Differential gene expression and pathway analyses were performed to identify genes and pathways modulated by these micronutrients.

Results: Global gene expression analysis revealed no significant individual genes that were associated with high intake of fish or tomato at baseline or after 3 months of supplementation with lycopene or fish oil. However, exploratory pathway analyses of rank-ordered genes (based on p-values not corrected for multiple comparisons) revealed the modulation of androgen and estrogen metabolism in men who routinely consumed more fish (p = 0.029) and tomato (p = 0.008) compared to men who ate less. In addition, modulation of arachidonic acid metabolism (p = 0.01) was observed after 3 months of fish oil supplementation compared with the placebo group; and modulation of nuclear factor (erythroid derived-2) factor 2 or Nrf2-mediated oxidative stress response for either supplement versus placebo (fish oil: p = 0.01, lycopene: p = 0.001).

Conclusions: We did not detect significant individual genes associated with dietary intake and supplementation of lycopene and fish oil. However, exploratory analyses revealed candidate in vivo pathways that may be modulated by these micronutrients.

Trial registration: ClinicalTrials.gov NCT00402285.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981–990.
    1. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008;112:1650–1659.
    1. Van Patten CL, de Boer JG, Tomlinson Guns ES. Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence. J Urol. 2008;180:2314–2321; discussion 2721–2312.
    1. Ornish D, Magbanua MJ, Weidner G, Weinberg V, Kemp C, et al. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A. 2008;105:8369–8374.
    1. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, et al. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res. 2006;12:4662–4670.
    1. Siler U, Herzog A, Spitzer V, Seifert N, Denelavas A, et al. Lycopene effects on rat normal prostate and prostate tumor tissue. J Nutr. 2005;135:2050S–2052S.
    1. Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst. 2001;93:1872–1879.
    1. Terry PD, Rohan TE, Wolk A. Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence. Am J Clin Nutr. 2003;77:532–543.
    1. Chavarro JE, Stampfer MJ, Hall MN, Sesso HD, Ma J. A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality. Am J Clin Nutr. 2008;88:1297–1303.
    1. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst. 2002;94:391–398.
    1. Augustsson K, Michaud DS, Rimm EB, Leitzmann MF, Stampfer MJ, et al. A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:64–67.
    1. Chan JM, Holick CN, Leitzmann MF, Rimm EB, Willett WC, et al. Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control. 2006;17:199–208.
    1. Chan JM, Weinberg V, Magbanua MJ, Sosa E, Simko J, et al. Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. Cancer Causes Control. 2011;22:141–150.
    1. Corridan BM, O'Donoghue M, Hughes DA, Morrissey PA. Low-dose supplementation with lycopene or beta-carotene does not enhance cell-mediated immunity in healthy free-living elderly humans. Eur J Clin Nutr. 2001;55:627–635.
    1. Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2001;10:861–868.
    1. Hininger IA, Meyer-Wenger A, Moser U, Wright A, Southon S, et al. No significant effects of lutein, lycopene or beta-carotene supplementation on biological markers of oxidative stress and LDL oxidizability in healthy adult subjects. J Am Coll Nutr. 2001;20:232–238.
    1. Hughes DA, Wright AJ, Finglas PM, Polley AC, Bailey AL, et al. Effects of lycopene and lutein supplementation on the expression of functionally associated surface molecules on blood monocytes from healthy male nonsmokers. J Infect Dis. 2000;182(Suppl 1):S11–15.
    1. Olmedilla B, Granado F, Southon S, Wright AJ, Blanco I, et al. A European multicentre, placebo-controlled supplementation study with alpha-tocopherol, carotene-rich palm oil, lutein or lycopene: analysis of serum responses. Clin Sci (Lond) 2002;102:447–456.
    1. Richelle M, Bortlik K, Liardet S, Hager C, Lambelet P, et al. A food-based formulation provides lycopene with the same bioavailability to humans as that from tomato paste. J Nutr. 2002;132:404–408.
    1. Neuman I, Nahum H, Ben-Amotz A. Reduction of exercise-induced asthma oxidative stress by lycopene, a natural antioxidant. Allergy. 2000;55:1184–1189.
    1. Aronson WJ, Glaspy JA, Reddy ST, Reese D, Heber D, et al. Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology. 2001;58:283–288.
    1. Luo J, Rizkalla SW, Vidal H, Oppert JM, Colas C, et al. Moderate intake of n-3 fatty acids for 2 months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men. Results of a controlled study. Diabetes Care. 1998;21:717–724.
    1. Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, et al. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. J Am Coll Cardiol. 1995;25:1492–1498.
    1. Tinker LF, Parks EJ, Behr SR, Schneeman BO, Davis PA. (n-3) fatty acid supplementation in moderately hypertriglyceridemic adults changes postprandial lipid and apolipoprotein B responses to a standardized test meal. J Nutr. 1999;129:1126–1134.
    1. Eritsland J, Arnesen H, Seljeflot I, Hostmark AT. Long-term metabolic effects of n-3 polyunsaturated fatty acids in patients with coronary artery disease. Am J Clin Nutr. 1995;61:831–836.
    1. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;130:554–562.
    1. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354:447–455.
    1. Mucci LA, Tamimi R, Lagiou P, Trichopoulou A, Benetou V, et al. Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int. 2001;87:814–820.
    1. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A. 2005;102:6092–6097.
    1. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B. 1995;57:289–300.
    1. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber R, editors. Bioinformatics and Computational Biology Solutions using R and Bioconductor. New York: Springer; 2005.
    1. Smyth GK. Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments. Statistical Applications in Genetics and Molecular Biology 2004
    1. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
    1. Magee JA, Araki T, Patil S, Ehrig T, True L, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 2001;61:5692–5696.
    1. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. Jama. 2002;287:1662–1670.
    1. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–15550.
    1. Klotz L. Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention. Nat Clin Pract Urol. 2008;5:2–3.
    1. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178:S14–19.
    1. Kenfield SA, Chang ST, Chan JM. Diet and Lifestyle Interventions in Active Surveillance Patients with Favorable-Risk Prostate Cancer. Curr Treat Options Oncol 2007
    1. Parsons JK, Newman V, Mohler JL, Pierce JP, Paskett E, et al. The Men's Eating and Living (MEAL) study: a Cancer and Leukemia Group B pilot trial of dietary intervention for the treatment of prostate cancer. Urology. 2008;72:633–637.
    1. Kucuk O, Sarkar FH, Djuric Z, Sakr W, Pollak MN, et al. Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med (Maywood) 2002;227:881–885.
    1. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267–273.
    1. Chung BH, Mitchell SH, Zhang JS, Young CY. Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells. Carcinogenesis. 2001;22:1201–1206.
    1. Shaikh IA, Brown I, Schofield AC, Wahle KW, Heys SD. Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway. Prostate. 2008;68:1635–1646.
    1. Narayanan NK, Narayanan BA, Reddy BS. A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors. Int J Oncol. 2005;26:785–792.
    1. Hughes-Fulford M, Li CF, Boonyaratanakornkit J, Sayyah S. Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer. Cancer Res. 2006;66:1427–1433.
    1. Hughes-Fulford M, Chen Y, Tjandrawinata RR. Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis. 2001;22:701–707.
    1. Hughes-Fulford M, Tjandrawinata RR, Li CF, Sayyah S. Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma cells. Carcinogenesis. 2005;26:1520–1526.
    1. Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, et al. Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev. 2004;28:8–16.
    1. Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev. 2000;9:1171–1182.
    1. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39–51.
    1. Hannun YA, Luberto C. Ceramide in the eukaryotic stress response. Trends Cell Biol. 2000;10:73–80.
    1. Tang L, Jin T, Zeng X, Wang JS. Lycopene inhibits the growth of human androgen-independent prostate cancer cells in vitro and in BALB/c nude mice. J Nutr. 2005;135:287–290.
    1. Ivanov NI, Cowell SP, Brown P, Rennie PS, Guns ES, et al. Lycopene differentially induces quiescence and apoptosis in androgen-responsive and -independent prostate cancer cell lines. Clin Nutr. 2007;26:252–263.
    1. Hwang ES, Bowen PE. Cell cycle arrest and induction of apoptosis by lycopene in LNCaP human prostate cancer cells. J Med Food. 2004;7:284–289.
    1. Moyad MA. Lifestyle/dietary supplement partial androgen suppression and/or estrogen manipulation. A novel PSA reducer and preventive/treatment option for prostate cancer? Urol Clin North Am. 2002;29:115–124, ix.
    1. Frohlich DA, McCabe MT, Arnold RS, Day ML. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene. 2008;27:4353–4362.
    1. Barve A, Khor TO, Nair S, Lin W, Yu S, et al. Pharmacogenomic profile of soy isoflavone concentrate in the prostate of Nrf2 deficient and wild-type mice. J Pharm Sci. 2008;97:4528–4545.
    1. Zhao CR, Gao ZH, Qu XJ. Nrf2-ARE signaling pathway and natural products for cancer chemoprevention. Cancer Epidemiol 2010
    1. Lee JS, Surh YJ. Nrf2 as a novel molecular target for chemoprevention. Cancer Lett. 2005;224:171–184.
    1. Kwak MK, Kensler TW. Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol. 2010;244:66–76.
    1. Kensler TW, Wakabayashi N. Nrf2: friend or foe for chemoprevention? Carcinogenesis. 2010;31:90–99.
    1. Lichtenstein AH, Russell RM. Essential nutrients: food or supplements? Where should the emphasis be? Jama. 2005;294:351–358.
    1. Basu A, Imrhan V. Tomatoes versus lycopene in oxidative stress and carcinogenesis: conclusions from clinical trials. Eur J Clin Nutr. 2007;61:295–303.
    1. Go VL, Nguyen CT, Harris DM, Lee WN. Nutrient-gene interaction: metabolic genotype-phenotype relationship. J Nutr. 2005;135:3016S–3020S.
    1. Hedelin M, Chang ET, Wiklund F, Bellocco R, Klint A, et al. Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer. 2007;120:398–405.
    1. Kaput J, Perlina A, Hatipoglu B, Bartholomew A, Nikolsky Y. Nutrigenomics: concepts and applications to pharmacogenomics and clinical medicine. Pharmacogenomics. 2007;8:369–390.
    1. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, et al. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009;101:306–320.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever